Ronnie C Mease1, Choong Mo Kang2, Vivek Kumar1, Sangeeta Ray Banerjee1, Il Minn1, Mary Brummet1, Kathleen L Gabrielson3, Yutian Feng2, Andrew Park1, Ana P Kiess4, George Sgouros1,4, Ganesan Vaidyanathan2, Michael R Zalutsky2, Martin G Pomper5,4. 1. Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Department of Radiology, Duke University Medical Center, Durham, North Carolina. 3. Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland; and. 4. Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland. 5. Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland; mpomper@jhmi.edu.
Abstract
α-Particle emitters targeting the prostate-specific membrane antigen (PSMA) proved effective in treating patients with prostate cancer who were unresponsive to the corresponding β-particle therapy. 211At is an α-emitter that may engender less toxicity than other α-emitting agents. We synthesized a new 211At-labeled radiotracer targeting PSMA that resulted from the search for a pharmacokinetically optimized agent. Methods: A small series of 125I-labeled compounds was synthesized from tin precursors to evaluate the effect of the location of the radiohalogen within the molecule and the presence of lutetium in the chelate on biodistribution. On that basis, 211At-3-Lu was selected and evaluated in cell uptake and internalization studies, and biodistribution and PSMA-expressing (PSMA+) PC3 PIP tumor growth control were evaluated in experimental flank and metastatic (PC3-ML-Luc) models. A long-term (13-mo) toxicity study was performed for 211At-3-Lu, including tissue chemistries and histopathology. Results: The radiochemical yield of 211At-3-Lu was 17.8% ± 8.2%. Lead compound 211At-3-Lu demonstrated total uptake within PSMA+ PC3 PIP cells of 13.4 ± 0.5% of the input dose after 4 h of incubation, with little uptake in control cells. In SCID mice, 211At-3-Lu provided uptake that was 30.6 ± 4.8 percentage injected dose per gram (%ID/g) in PSMA+ PC3 PIP tumor at 1 h after injection, and this uptake decreased to 9.46 ± 0.96 %ID/g by 24 h. Tumor-to-salivary gland and tumor-to-kidney ratios were 129 ± 99 at 4 h and 130 ± 113 at 24 h, respectively. Deastatination was not significant (stomach, 0.34 ± 0.20 %ID/g at 4 h). Dose-dependent survival was demonstrated at higher doses (>1.48 MBq) in both flank and metastatic models. There was little off-target toxicity, as demonstrated by hematopoietic stability, unchanged tissue chemistries, weight gain rather than loss throughout treatment, and favorable histopathologic findings. Conclusion: Compound 211At-3-Lu or close analogs may provide limited and acceptable toxicity while retaining efficacy in management of prostate cancer.
α-Particle emitters targeting the prostate-specific membrane antigen (PSMA) proved effective in treating patients with prostate cancer who were unresponsive to the corresponding β-particle therapy. 211At is an α-emitter that may engender less toxicity than other α-emitting agents. We synthesized a new 211At-labeled radiotracer targeting PSMA that resulted from the search for a pharmacokinetically optimized agent. Methods: A small series of 125I-labeled compounds was synthesized from tin precursors to evaluate the effect of the location of the radiohalogen within the molecule and the presence of lutetium in the chelate on biodistribution. On that basis, 211At-3-Lu was selected and evaluated in cell uptake and internalization studies, and biodistribution and PSMA-expressing (PSMA+) PC3 PIP tumor growth control were evaluated in experimental flank and metastatic (PC3-ML-Luc) models. A long-term (13-mo) toxicity study was performed for 211At-3-Lu, including tissue chemistries and histopathology. Results: The radiochemical yield of 211At-3-Lu was 17.8% ± 8.2%. Lead compound 211At-3-Lu demonstrated total uptake within PSMA+ PC3 PIP cells of 13.4 ± 0.5% of the input dose after 4 h of incubation, with little uptake in control cells. In SCID mice, 211At-3-Lu provided uptake that was 30.6 ± 4.8 percentage injected dose per gram (%ID/g) in PSMA+ PC3 PIP tumor at 1 h after injection, and this uptake decreased to 9.46 ± 0.96 %ID/g by 24 h. Tumor-to-salivary gland and tumor-to-kidney ratios were 129 ± 99 at 4 h and 130 ± 113 at 24 h, respectively. Deastatination was not significant (stomach, 0.34 ± 0.20 %ID/g at 4 h). Dose-dependent survival was demonstrated at higher doses (>1.48 MBq) in both flank and metastatic models. There was little off-target toxicity, as demonstrated by hematopoietic stability, unchanged tissue chemistries, weight gain rather than loss throughout treatment, and favorable histopathologic findings. Conclusion: Compound 211At-3-Lu or close analogs may provide limited and acceptable toxicity while retaining efficacy in management of prostate cancer.
Authors: Takahito Nakajima; Makoto Mitsunaga; Neil H Bander; Warren D Heston; Peter L Choyke; Hisataka Kobayashi Journal: Bioconjug Chem Date: 2011-07-27 Impact factor: 4.774
Authors: Ana P Kiess; Il Minn; Ganesan Vaidyanathan; Robert F Hobbs; Anders Josefsson; Colette Shen; Mary Brummet; Ying Chen; Jaeyeon Choi; Eftychia Koumarianou; Kwamena Baidoo; Martin W Brechbiel; Ronnie C Mease; George Sgouros; Michael R Zalutsky; Martin G Pomper Journal: J Nucl Med Date: 2016-05-26 Impact factor: 10.057
Authors: Sangeeta Ray Banerjee; Vivek Kumar; Ala Lisok; Jian Chen; Il Minn; Mary Brummet; Srikanth Boinapally; Michael Cole; Ethel Ngen; Bryan Wharram; Cory Brayton; Robert F Hobbs; Martin G Pomper Journal: Eur J Nucl Med Mol Imaging Date: 2019-08-10 Impact factor: 9.236
Authors: Christian M Zechmann; Ali Afshar-Oromieh; Tom Armor; James B Stubbs; Walter Mier; Boris Hadaschik; John Joyal; Klaus Kopka; Jürgen Debus; John W Babich; Uwe Haberkorn Journal: Eur J Nucl Med Mol Imaging Date: 2014-02-28 Impact factor: 9.236
Authors: Alfred Morgenstern; Christos Apostolidis; Clemens Kratochwil; Mike Sathekge; Leszek Krolicki; Frank Bruchertseifer Journal: Curr Radiopharm Date: 2018
Authors: José Carlos Dos Santos; Martin Schäfer; Ulrike Bauder-Wüst; Wencke Lehnert; Karin Leotta; Alfred Morgenstern; Klaus Kopka; Uwe Haberkorn; Walter Mier; Clemens Kratochwil Journal: Eur J Nucl Med Mol Imaging Date: 2019-01-03 Impact factor: 9.236
Authors: Sashi Debnath; Ning Zhou; Mark McLaughlin; Samuel Rice; Anil K Pillai; Guiyang Hao; Xiankai Sun Journal: Int J Mol Sci Date: 2022-01-21 Impact factor: 5.923